ProCE Banner Activity

Abstract: Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.

PDF

Richard S. Finn, MD discusses "Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study." in this virtual poster presentation.

Released: January 26, 2023

Expiration: January 25, 2024

Faculty

Richard S. Finn

Richard S. Finn, MD

Professor
Department of Medicine
Division of Hematology/Oncology
UCLA David Geffen School of Medicine
Medical Director, Clinical Research Unit
Director, Signal Transduction and Therapeutics Program
University of California, Los Angeles
Los Angeles, California